Abstract
Pathogenic bacteria such as the drug-resistant strains of Staphylococcus aureus dominate our medical and environmental landscape, causing hundreds of thousands of deaths from infections and life-threatening complications following surgeries. The availability of antibiotics and treatment protocols to control these microbes are becoming increasingly more limited as antibiotic resistance becomes more prevalent. In this article, a new family of small molecules referred to as N-organothio β-lactams is presented that have unique features and a mode of action against these pathogenic microbes, including multi-drug resistant strains, that may offer new options to address these concerns. This review gives an overview of the initial discovery, exploration and ongoing development of these synthetic antibacterial agents, with a focus on their unique properties and capabilities that provide fresh opportunities for combating pathogenic bacteria.